Temsirolimus Plus Bortezomib Safe, Active for Relapsed/Refractory B-Cell NHL
the ONA take:
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe and has activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma, a recent study published in the journal Cancer has shown.
For the single-arm, phase 2 trial, researchers enrolled 39 patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
The patients received bortezomib and temsirolimus weekly on days 1, 8, 15, and 22 of a 35-day cycle. This dosing scheme has previously been studied in patients with multiple myeloma.
Results showed that 7.7% of patients achieved a complete response and 23% achieved a partial response. Median progression-free survival was 4.7 months (2 months for patients with diffuse large B-cell lymphoma, 7.5 months for those with mantle cell lymphoma, and 16.5 months for those with follicular lymphoma).
Researchers found that two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. In regard to safety, there were no unexpected toxicities with the combination.
“Further studies with this combination are warranted in specific subtypes of NHL,” the authors conclude.
The combination of a mammalian target of rapamycin inhibitor and a proteasome inhibitor is safe in B-cell non-Hodgkin lymphoma.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|